The prognosis of GBM patients with high levels of PLD1 and CD44 was poor, compared with cohorts with low levels of PLD1 and CD44 in the TCGA (Cancer Genome Atlas Research Network, 2008, Figure 1D). The gene discussed is CD44; the disease is glioblastoma.